Lensar Inc. logo

Lensar Inc. (LNSR)

Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
5. 80
+0.13
+2.2928%
$
69.72M Market Cap
- P/E Ratio
- Div Yield
18,500 Volume
-1.03 Eps
$ 5.67
Previous Close
Add Transaction
Day Range
5.64 5.82
Year Range
5.06 13.43
Want to track LNSR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
LENSAR Q1 Earnings Call Highlights

LENSAR Q1 Earnings Call Highlights

LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.

Marketbeat | 2 months ago
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q4 2025 Earnings Call Transcript

Seekingalpha | 3 months ago
LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning and thank you for your participation. At this time, all participants are in listen-only mode.

Seekingalpha | 1 year ago
Medical Devices Firm Lensar Surges Ahead On Robotic Technology

Medical Devices Firm Lensar Surges Ahead On Robotic Technology

LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company's ALLY Robotic Cataract Laser System has driven significant revenue and earnings growth, with a one-year price target of $15.15, a 42.21% increase. Despite competition from larger firms, LENSAR's disruptive technology, expanding market share, and strong management team position it well for long-term growth.

Seekingalpha | 1 year ago
LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning, and thank you for participation. At this time, all participants are in a listen-only mode.

Seekingalpha | 1 year ago
LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript

LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript

LENSAR, Inc. (NASDAQ:LNSR ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. [Operator Instructions].

Seekingalpha | 1 year ago